Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)

Next Previous
X
Search
Trial Profile

Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vistusertib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SUKSES-D

    • Most Recent Events

    • 25 Jun 2020 Results of pooled analysis from SUKSES C, SUKSES D, SUKSES N1 and SUKSES N3 published in the Cancer.
    • 04 Jun 2019 Results assessing efficacy of AZD1775, AZD2014, AZD2811 in 3 trials (NCT02593019, NCT03106155, NCT03366675), presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Sep 2018 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top